Introduction {#sec1}
============

Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) have the ability to self-replicate and to differentiate into all types of body cells including hepatoblasts and hepatocytes. Although cryopreserved primary human hepatocytes are useful in drug screening and liver cell transplantation, they rapidly lose their functions (such as drug metabolism capacity) and hardly proliferate in in vitro culture systems. On the other hand, human hepatic stem cells from fetal and postnatal human liver are able to self-replicate and able to differentiate into hepatocytes ([@bib11; @bib20]). However, the source of human hepatic stem cells is limited, and these cells are not available commercially. Therefore, the human pluripotent stem cell (hPSC)-derived hepatoblast-like cells (HBCs), which have potential to differentiate into the hepatocyte-like cells, would be an attractive cell source to provide abundant hepatocyte-like cells for drug screening and liver cell transplantation.

Because expandable and multipotent hepatoblasts or hepatic stem cells are of value, suitable culture conditions for the maintenance of hepatoblasts or hepatic stem cells obtained from fetal or adult mouse liver were developed ([@bib5; @bib17]). Soluble factors, such as hepatocyte growth factor (HGF) and epidermal growth factor (EGF), are known to support the proliferation of mouse hepatic stem cells and hepatoblast ([@bib5; @bib17]). Extracellular matrix (ECM) also affects the maintenance of hepatoblasts or hepatic stem cells. Laminin can maintain the character of mouse hepatoblasts (Dlk1-positive cells) ([@bib17]). However, the methodology for maintaining HBCs differentiated from hPSCs has not been well investigated. [@bib21] have reported that hESC-derived hepatoblast-like cells (sorted N-cadherin-positive cells were used) could be maintained on STO feeder cells. Although a culture system using STO feeder cells for the maintenance of hepatoblast-like cells might be useful, there are two problems. The first problem is that N-cadherin is not a specific marker for human hepatoblasts. N-cadherin is also expressed in hESC-derived mesendoderm cells and definitive endoderm (DE) cells ([@bib12]). The second problem is that residual undifferentiated cells could be maintained on STO feeder cells. Therefore, their culture condition cannot rule out the possibility of the proliferation of residual undifferentiated cells. Because it is known that hPSC-derived cells have the potential to form teratomas in the host, the production of safer hepatocyte-like cells or hepatoblast-like cells has been required. Therefore, we decided to purify hPSC-derived HBCs, which can differentiate into mature hepatocyte-like cells, and then expand these cells.

In this study, we attempt to determine a suitable culture condition for the extensive expansion of HBCs derived from hPSCs. We found that the HBCs derived from hPSCs can be maintained and proliferated on human laminin-111 (LN111)-coated dishes. To demonstrate that expandable, multipotent, and safe (i.e., devoid of residual undifferentiated cells) hPSC-derived HBCs could be maintained under our culture condition, the hPSC-derived HBCs were used for hepatic and biliary differentiation, colony assay, and transplantation into immunodeficient mice.

Results {#sec2}
=======

Human PSC-Derived Hepatoblast-like Cells Could Adhere onto Human LN111 via Integrin α6 and β1 {#sec2.1}
---------------------------------------------------------------------------------------------

The HBCs were generated from hPSCs (hESCs and hiPSCs) as described in [Figure 1](#fig1){ref-type="fig"}A (details of the characterization of hPSC-derived HBCs are described in [Figure 3](#fig3){ref-type="fig"}). Definitive endoderm differentiation of hPSCs was promoted by stage-specific transient transduction of FOXA2 in addition to the treatment with appropriate soluble factors (such as Activin A). Overexpression of FOXA2 is not necessary for establishing the hPSC-derived HBCs, but it is helpful for efficient generation of the hPSC-derived HBCs. On day 9, these hESC-derived populations contained two cell populations with distinct morphology ([Figure 1](#fig1){ref-type="fig"}B). One population resembled human hepatic stem cells that were isolated from human fetal liver (shown in red) ([@bib11]), whereas the other population resembled definitive endoderm cells (shown in green) ([@bib3]). The population that resembled human hepatic stem cells was alpha-1-fetoprotein (AFP) positive, whereas the other population was AFP negative ([Figure 1](#fig1){ref-type="fig"}C, left). On day 9, the percentage of AFP-positive cells was approximately 80% ([Figure 1](#fig1){ref-type="fig"}C, right). To characterize these two cell populations (hESC-derived HBC and non-HBC \[NHBC\] populations), the colonies were manually isolated by using a pipette, and then the gene expression analysis was performed. The gene expression levels of *AFP*, *CD133*, *EpCAM*, *CK8*, and *CK18* in the hESC-derived HBCs were higher than those in the bulk population containing both hESC-derived HBCs and NHBCs (*CD133*, *EpCAM*, *CK8*, and *CK18* were named as pan-hepatoblast markers and are known to be strongly expressed in both human hepatic stem cells and hepatoblasts \[[@bib11; @bib20]\]) ([Figure 1](#fig1){ref-type="fig"}D). On the other hand, the gene expressions of *AFP*, *CD133*, *EpCAM*, *CK8*, and *CK18* in the hESC-derived NHBCs were hardly detected. The gene expression levels of DE, mesendoderm, and pluripotent markers in the hESC-derived NHBCs were higher than those in the hESC-derived HBCs, indicating that the hESC-derived NHBCs could remain in a more undifferentiated state than the hESC-derived HBCs ([Figures S1](#app2){ref-type="sec"}A--S1C available online). These results suggest that hepatoblast-like cells could be differentiated from hPSCs.

To purify the hESC-derived HBCs, these cells were plated onto dishes coated with various laminins. There are 15 different laminin isoforms in human tissues. Although laminin is known to be useful to sustain mouse hepatoblasts ([@bib17]), it remains unknown which human laminin isoform has the potential to purify and expand the HBCs. To identify a human laminin isoform that would be useful for purifying hESC-HBCs, the hESC-HBCs and -NHBCs were plated onto dishes coated with various types of commercially available human laminins ([Figure 1](#fig1){ref-type="fig"}E). The hESC-derived HBCs could more efficiently adhere onto the human LN111-coated dish compared with hESC-derived NHBCs or unseparated populations (containing both HBCs and NBCs). These data suggest that a hESC-derived HBC population can be purified from the unseparated populations by culturing on human LN111-coated dishes. Because integrins are known to be important molecules for cell adhesion to the ECM including laminins, we expected that certain types of integrins would allow selective adhesion of the hESC-derived HBCs to human LN111-coated dish. The gene expression levels of various integrins were examined ([Figure 1](#fig1){ref-type="fig"}F). Among the integrin α subunits, the gene expression level of *integrin α6* in the hESC-derived HBCs was significantly higher than that in the hESC-derived NHBCs. In contrast, among the integrin β subunits, the gene expression level of *integrin β1* was higher than those of *integrin β2* and *β3* in all cell populations. The hESC-derived HBCs, but not NHBCs, expressed both integrin α6 and β1 ([Figure S1](#app2){ref-type="sec"}D). Almost all adhesion of the hESC-derived HBCs to a human LN111-coated dish was inhibited by both function-blocking antibodies to integrin α6 and β1 ([Figure 1](#fig1){ref-type="fig"}G). These results indicated that the hESC-derived HBCs could attach to a human LN111-coated dish via integrin α6 and β1.

The hPSC-Derived HBCs Could Be Proliferated and Maintained on a Human LN111-Coated Dish {#sec2.2}
---------------------------------------------------------------------------------------

To obtain the purified hESC-derived HBC population, the hESC-derived cells (day 9) were plated onto a human LN111-coated dish, and then unattached cells were removed at 15 min after plating ([Figure 2](#fig2){ref-type="fig"}A). Among various laminins, only human LN111 could proliferate ([Figure 2](#fig2){ref-type="fig"}B) and purify ([Figure 2](#fig2){ref-type="fig"}C) the AFP-positive population in the presence of HGF and EGF. During culture on the human LN111-coated dish, the morphology of the hESC-derived HBCs gradually changed into that of human hepatoblasts ([Figure S1](#app2){ref-type="sec"}E) ([@bib11]). Therefore, the characteristics of hESC-derived HBCs might be changed by culturing on a human LN111-coated dish (details of the characterization of the hESC-derived HBCs are described in [Figure 3](#fig3){ref-type="fig"}). After culturing on a human LN111-coated dish for a week, almost all of the cells were still AFP positive ([Figures 2](#fig2){ref-type="fig"}C and 2D). To characterize the cells cultured on various types of human laminins for 7 days, the gene expression levels of *AFP* and pan-hepatoblast (*CD133*, *CK8*, *CK18*, and *EpCAM*) markers were examined on day 16 ([Figure 2](#fig2){ref-type="fig"}E). The gene expression levels of *AFP* and pan-hepatoblast markers in the hESC-derived HBCs P1 (HBCs passaged once) did not change as compared with those of the hESC-derived HBCs (day 9; HBC P0) (the definitions of HBC P0, P1, P10, and clone in the present study are shown in [Figure S3](#app2){ref-type="sec"}). The gene expression levels of mature hepatocyte and cholangiocyte markers in the hESC-derived HBC P1 did not change as compared with those of the hESC-derived HBC P0 (day 9) ([Figure S1](#app2){ref-type="sec"}F). These results suggest that the characteristics of the hESC-derived HBC P1 are similar to those of the hESC-derived HBC P0, although their morphologies are quite different from each other. Interestingly, the gene expression levels of mature cholangiocyte markers in the cells cultured on human LN411- or 511-coated dishes were upregulated as compared with those of the hESC-derived HBC P0 (day 9) ([Figure S1](#app2){ref-type="sec"}F), suggesting that human LN411 and 511 might promote biliary differentiation. Importantly, both hESC-derived HBCs and hiPSC-derived HBCs could extensively proliferate on a human LN111-coated dish for more than 15 passages ([Figure 2](#fig2){ref-type="fig"}F) in the presence of HGF and EGF. Doubling times of hESC (H9)-derived HBCs and hiPSC (Dotcom)-derived HBCs were approximately 78 and 67 hr, respectively. Almost all of the populations cultured on a human LN111-coated dish were AFP positive ([Figure 2](#fig2){ref-type="fig"}G). Taken together, these results suggested that the hPSC-derived HBCs would proliferate and be maintained on a human LN111-coated dish.

Characterization of the hESC-Derived HBCs {#sec2.3}
-----------------------------------------

To characterize the hESC-derived HBCs, the gene expression profiles in the hESC-derived purified HBCs (HBC P0), short-term cultured HBCs (HBCs passaged once \[HBC P1\]), and long-term cultured HBC (HBCs passaged ten times \[HBC P10\]) were examined. The hESC-derived HBCs were AFP positive ([Figure 3](#fig3){ref-type="fig"}A). Although the hESC-derived HBC P0 were negative for ALB, CK7, and CK19, the hESC-derived HBC P1 and P10 were positive for these genes ([Figure 3](#fig3){ref-type="fig"}A). Both integrin α6 and β1 (receptors of LN111) were strongly expressed in the hESC-derived HBC P0, P1, and P10 ([Figure 3](#fig3){ref-type="fig"}B). The gene expression levels of human hepatic stem cell markers (*N-CAM* and *Claudin 3* \[[@bib11]\]; these are not expressed in human hepatoblasts) in the hESC-derived HBC P0 were higher than those of the hESC-derived HBC P1 and P10 ([Figure 3](#fig3){ref-type="fig"}C). However, the gene expression level of *CK19* in the hESC-derived HBC P0 was lower than that of the hESC-derived HBC P1 and P10. The gene expression levels of pan-hepatoblast markers in the hESC-derived HBC P0 were similar to those of the hESC-derived HBC P1 and P10 ([Figure 3](#fig3){ref-type="fig"}D). The gene expression levels of human hepatoblast markers (*ALB*, *CYP3A7*, and *I-CAM* ([@bib11]), none of which were expressed in human hepatic stem cells) in the hESC-derived HBC P1 and P10 were higher than those of the hESC-derived HBC P0 ([Figure 3](#fig3){ref-type="fig"}E). However, the AFP expression level in the hESC-derived HBC P0 was similar to that of the hESC-derived HBC P1 and P10. Because the gene expression levels of mature hepatocyte and cholangiocyte markers in the hESC-derived HBC P1 and P10 were not increased as compared with those in the hESC-derived HBC P0 ([Figure 3](#fig3){ref-type="fig"}F), the hESC-derived HBC P1 and P10 were not segregated into either of the hepatic and biliary lineages. We also examined the gene expression levels of hepatoblast markers, which have been reported only in mice and not in humans ([Figure 3](#fig3){ref-type="fig"}G). The characteristics of the hPSC-derived HBCs are summarized in [Figure S3](#app2){ref-type="sec"}. In addition, hESC-derived HBC P0 and HBC P10 showed normal karyotypes ([Figure S2](#app2){ref-type="sec"}A). Therefore, the genetic stability of the HBCs was confirmed throughout the maintenance period. Taken together, these results suggest that the hESC-derived HBC P0 resemble human hepatic stem cells and the hESC-derived HBC P1 and P10 resemble human hepatoblasts, although some gene expression patterns in the hESC-derived HBCs differ from those in human hepatic stem cells and human hepatoblasts, respectively.

In order to examine whether the hESC-derived HBC P0 have the potential to proliferate clonally on various types of human laminins, single HBCs were plated on separate wells of a human LN111-coated 96-well plate at a low density (one cell per one well) ([Table S1](#app2){ref-type="sec"}). Single cells that attached to the human LN111-coated dish were AFP positive and HNF4α positive ([Figure S2](#app2){ref-type="sec"}B). At 7 days after plating, the hESC-derived HBC colonies (albumin \[ALB\]- and cytokeratin 7 \[CK7\] double positive) (a representative colony is shown in [Figure S2](#app2){ref-type="sec"}C) were efficiently generated from the hESC-derived HBC P0 on a LN111-coated dish. Taken together, these results showed that the hESC-derived HBCs could be generated from both the hESC-derived HBC P0 population and the single hESC-derived HBC P0.

The hPSC-Derived HBCs Could Differentiate into Both Hepatic and Biliary Lineages In Vitro {#sec2.4}
-----------------------------------------------------------------------------------------

To examine whether the hESC-derived HBCs have the potential to differentiate into both hepatic and biliary lineages, first, these cells were differentiated into hepatocyte-like cells as described in [Figure 4](#fig4){ref-type="fig"}A. After 2 weeks of hepatic differentiation, almost all of the cells were polygonal in shape ([Figure 4](#fig4){ref-type="fig"}B) and were CYP3A4, αAT, and ALB positive ([Figure 4](#fig4){ref-type="fig"}C). The gene expression levels of mature hepatocyte markers in the HBC P0-, HBC P10-, or HBC clone-derived hepatocyte-like cells were higher than those in the cells that had not undergone hepatic differentiation ([Figure 4](#fig4){ref-type="fig"}D), although the gene expression levels of mature cholangiocyte markers in these cells did not change ([Figure 4](#fig4){ref-type="fig"}E). The ASGR1-positive cells in the HBC P0-, HBC P10-, and HBC clone-derived population accounted for approximately 60%, 90%, and 90% of the total, respectively ([Figure 4](#fig4){ref-type="fig"}F). The HBC P0-, HBC P10-, or HBC clone-derived hepatocyte-like cells had the ability to produce ALB ([Figure 4](#fig4){ref-type="fig"}G, left) and urea ([Figure 4](#fig4){ref-type="fig"}G, right). Next, the hESC-derived HBCs were differentiated into cholangiocyte-like cells as described in [Figure 4](#fig4){ref-type="fig"}H. After 2 weeks of biliary differentiation, tubular structures ([Figure 4](#fig4){ref-type="fig"}I) that were CK7 positive ([Figure 4](#fig4){ref-type="fig"}J) were observed. Although the gene expression levels of mature hepatocyte markers ([Figure 4](#fig4){ref-type="fig"}K) in the HBC P0-, HBC P10-, or HBC clone-derived cholangiocyte-like cells did not change, the gene expression levels of mature cholangiocyte markers ([Figure 4](#fig4){ref-type="fig"}L) in these cells were higher than those in the cells that had not undergone differentiation. Similar results were obtained by using another hESC line (H1) and hiPSC line (Dotcom) ([Figure S4](#app2){ref-type="sec"}). Moreover, HBC-derived hepatocyte-like cells exhibited CYP metabolism capacity ([Figure S5](#app2){ref-type="sec"}A) and a functional urea cycle that could response to ammonia ([Figure S5](#app2){ref-type="sec"}B) and were considered to have potential to be applied in the prediction of drug-induced hepatotoxicity ([Figure S5](#app2){ref-type="sec"}C). Taken together, these results indicated that the hPSC-derived HBCs have the ability to differentiate into both hepatic and biliary lineages in vitro.

In Vivo Cell Transplantation Assays of the hPSC-Derived HBCs {#sec2.5}
------------------------------------------------------------

To examine whether the hESC-derived HBCs could be used for hepatocyte transplantation, these cells were transplanted into CCl~4~-treated immunodeficient mice as shown in [Figure 5](#fig5){ref-type="fig"}A. The hepatocyte functionality of the hESC-derived HBC P0 or HBC P10 was assessed by measuring secreted human ALB levels in the recipient mice ([Figure 5](#fig5){ref-type="fig"}B). Although human ALB was detected in the mice that were transplanted with the hESC-derived HBC P0 or HBC P10, it was not detected in the mice that were not transplanted with these cells. The ALB-positive cells were observed in mice transplanted with the hESC-derived HBC P0 or HBC P10 ([Figure 5](#fig5){ref-type="fig"}C). Most of the ALB-positive cells in mice transplanted with the hESC-derived HBC P10 were AFP negative ([Figure 5](#fig5){ref-type="fig"}D), indicating that transplanted hESC-derived HBCs were differentiated into mature hepatocyte-like cells (some of them were binuclear \[[Figure 5](#fig5){ref-type="fig"}E, white arrows\]). These results demonstrated that hESC-derived HBCs have the potential to be applied for hepatocyte transplantation.

Discussion {#sec3}
==========

The main purpose of this study was to establish and characterize expandable HBCs from hPSCs. First, we identified that human LN111 could support self-renewal and proliferation of hPSC-derived HBCs in the presence of HGF and EGF. Second, we showed that the hPSC-derived HBCs have the potential to segregate into both hepatic and biliary lineages, and to integrate into the mouse liver parenchyma.

We have demonstrated that the hPSC-derived HBCs could be maintained on a human LN111-coated dish in an integrin α6- and β1-dependent manner ([Figure 1](#fig1){ref-type="fig"}). It is known that undifferentiated hPSCs could be maintained on a human LN511-coated dish but not on a human LN111-coated dish ([@bib10]). This might suggest that human LN111 has the potential not only to selectively maintain HBCs, but also to eliminate residual undifferentiated cells. Our hepatoblast-like cells could efficiently proliferate for more than 3 months on a human LN111-coated dish ([Figure 2](#fig2){ref-type="fig"}). In the human liver development (during 5--10 weeks gestation), laminin is observed in both the perisinusoidal space and portal tracts ([@bib2]). The expression of laminin is localized around the periportal biliary trees during the later stage of liver development ([@bib2]). Hepatic stem cells reside around the hepatic portal area ([@bib1]). It is also known that laminin is accumulated around oval cells although laminin is not expressed around quiescent mature hepatocytes ([@bib9]). These facts suggest that laminin plays an important role in the maintenance and proliferation of hepatoblasts.

The hPSC-derived HBC P10 and clone were positive for hepatoblast markers (AFP, ALB, CYP3A7, and I-CAM), but negative for hepatic stem cell markers (N-CAM and Claudin 3) ([Figure 3](#fig3){ref-type="fig"}) ([@bib11]). Although the hPSC-derived HBCs were able to expand on human LN111-coated dish, Schmelzer et al. showed that human hepatoblasts do not proliferate under a monolayer culture condition, but human hepatic stem cells could self-replicate for more than 6 months ([@bib11]). Although further investigations of the hepatoblast characteristics in the hPSC-derived HBCs will be needed in the future, the results in the present study suggest that the characteristics of hPSC-derived HBCs expanded on human LN111-coated dishes were similar to those in human hepatoblasts isolated from the human liver ([@bib11; @bib20]).

The hPSC-derived HBCs had the ability to integrate into the mouse liver parenchyma ([Figure 5](#fig5){ref-type="fig"}), in the manner of human hepatic stem cells or hepatoblasts ([@bib11]). The human ALB serum levels (approximately 20--70 ng/ml) in mice transplanted with the hESC-derived HBC P0 or HBC P10 were comparable to those in the previous paper in which the hESC-derived definitive endoderm cells, hepatoblasts, and hepatocyte-like cells were transplanted into mice ([@bib6]), but were lower than those of human liver chimeric mice ([@bib19]). Human ALB serum levels would increase if more suitable host mice, such as urokinase plasminogen activator-SCID mice were used ([@bib19]).

In this study, we have developed a technology for the maintenance and proliferation of hPSC-derived HBCs by using human LN111. To transplant these cells for purposes of regenerative medicine, a xeno-free culture condition for hPSC-derived HBCs must be developed in the future. It is hoped that the hPSC-derived HBCs and their derivatives will be helpful in various medical applications, such as drug screening and regenerative medicine.

Experimental Procedures {#sec4}
=======================

hESC and hiPSC Culture {#sec4.1}
----------------------

The hESC lines (H1 \[WA01\] and H9 \[WA09\] \[WiCell Research Institute\]) and the hiPSC line, Dotcom (JCRB number: JCRB1327) ([@bib7; @bib8]), were maintained on a feeder layer of mitomycin-C-treated mouse embryonic fibroblasts (Millipore) with ReproStem medium (ReproCELL) supplemented with 5 and 10 ng/ml fibroblast growth factor 2 (FGF2) (Katayama Kagaku Kogyo), respectively. H1 and H9 were used following the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and, furthermore, the study was approved by an independent ethics committee.

In Vitro Hepatoblast Differentiation {#sec4.2}
------------------------------------

The differentiation protocol for the induction of definitive endoderm cells and hepatoblasts was based on our previous report with some modifications ([@bib4; @bib14; @bib15; @bib16]). In mesendoderm differentiation, hESCs/iPSCs were cultured for 2 days on Matrigel (BD Biosciences) in differentiation hESF-DIF medium that contains 100 ng/ml Activin A (R&D Systems) (hESF-DIF medium was purchased from Cell Science & Technology Institute; differentiation hESF-DIF medium was supplemented with 10 μg/ml human recombinant insulin, 5 μg/ml human apotransferrin, 10 μM 2-mercaptoethanol, 10 μM ethanolamine, 10 μM sodium selenite, and 0.5 mg/ml bovine fatty acid free serum albumin \[all from Sigma\]). To generate definitive endoderm cells, the mesendoderm cells (day 2) were transduced with 3,000 vector particle (VP)/cell of FOXA2-expressing adenovirus vectors (Ad-FOXA2) for 1.5 hr and cultured until day 6 on Matrigel in differentiation hESF-DIF medium supplemented with 100 ng/ml Activin A. For induction of hepatoblasts, the definitive endoderm cells were cultured for 3 days on a Matrigel in differentiation hESF-DIF medium supplemented with 30 ng/ml bone morphogenetic protein 4 (BMP4) (R&D Systems) and 20 ng/ml FGF4 (R&D Systems).

Establishment and Maintenance of the hPSC-Derived HBCs {#sec4.3}
------------------------------------------------------

The hPSC-derived HBCs were first purified from the hPSC-derived cells (day 9) by selecting attached cells on a human recombinant LN111 (BioLamina)-coated dish at 15 min after plating. The hPSC-derived HBCs were cultured on a human LN111-coated dish (2.0 × 10^4^ cells/cm^2^) in maintenance DMEM/F12 medium (DMEM/F12 medium \[Invitrogen\] was supplemented with 10% FBS, 1 × insulin/transferrin/selenium, 10 mM nicotinamide, 10^−7^ M dexamethasone (DEX) (Sigma), 20 mM HEPES, 25 mM NaHCO~3~, 2 mM L-glutamine, penicillin/streptomycin, 40 ng/ml hepatocyte growth factor \[HGF\] \[R&D Systems\] and 20 ng/ml epidermal growth factors \[EGF\] \[R&D Systems\]). The medium was refreshed every day. The hPSC-derived HBCs were dissociated with Accutase (Millipore) into single cells and subcultured every 6 or 7 days.

Establishment and Maintenance of a Single hPSC-Derived HBC {#sec4.4}
----------------------------------------------------------

For single-cell culture, the single HBC was plated to separate well of human LN111-coated 96-well plate in maintenance DMEM/F12 medium supplemented with 25 μM Y-27632 (ROCK inhibitor) (Millipore), and then colonies derived from a single cell were manually picked up and cultured as well as HBCs (these cells were designated the HBC clone).

In Vitro Hepatocyte and Cholangiocyte Differentiation {#sec4.5}
-----------------------------------------------------

To induce hepatocyte differentiation, the hPSC-derived HBC P0, HBC P10, and HBC clone were cultured for 14 days on a Matrigel-coated dish (7.5 × 10^4^ cells/cm^2^) in HCM (Lonza) supplemented with 20 ng/ml HGF, 20 ng/ml Oncostatin M (OsM) (R&D Systems), and 10^−6^ M DEX. To induce cholangiocyte differentiation, the hPSC-derived HBC P0, HBC P10, and HBC clone were cultured in collagen gel for 14 days. To establish collagen gel plates, 500 μl collagen gel solution (consisting of 400 μl type I-A Collagen (Nitta gelatin), 50 μl 10 × DMEM, and 50 μl of 200 mM HEPES buffer containing 2.2% NaHCO~3~ and 0.05 M NaOH) was added to each well, and then the plates were incubated at 37°C for 30 min. The hPSC-derived HBC P0, HBC P10, and HBC clone (5 × 10^4^ cells) were resuspended in 500 μl differentiation DMEM/F12 medium (differentiation DMEM/F12 medium was supplemented with 20 mM HEPES, 2 mM L-glutamine, 100 ng/ml EGF, and 40 ng/ml insulin-like growth factor 2 \[ILGF2\]), and then mixed with 500 μl of the collagen gel solution and plated onto the basal layer of collagen. After 30 min, 2 ml of differentiation DMEM/F12 medium was added to the well.

Ad Vectors {#sec4.6}
----------

Ad vectors were constructed by an improved in vitro ligation method. The human EF-1α promoter-driven FOXA2-expressing Ad vectors (Ad-FOXA2) were constructed previously ([@bib15]). All of Ad vectors contain a stretch of lysine residue (K7) peptides in the C-terminal region of the fiber knob for more efficient transduction of hESCs, hiPSCs, mesendoderm cells, and definitive endoderm cells, in which transfection efficiency was almost 100%, and purified as described previously ([@bib4; @bib13; @bib18]). The VP titer was determined by using a spectrophotometric method.

Flow Cytometry {#sec4.7}
--------------

Single-cell suspensions of the hPSC-derived cells were fixed with 4% paraformaldehyde (PFA) at 4°C for 10 min and then incubated with the primary antibody (described in [Table S2](#app2){ref-type="sec"}), followed by the secondary antibody (described in [Table S3](#app2){ref-type="sec"}). Control cells were incubated with anti-mouse, goat, or rabbit immunoglobulin (Ig) G antibodies (Santa Cruz Biotechnology) and then incubated with the secondary antibody. Flow cytometry analysis was performed using a fluorescence-activated cell sorting (FACS) LSR Fortessa flow cytometer (BD Biosciences). Cell sorting was performed using a FACS Aria (BD Biosciences).

RNA Isolation and RT-PCR {#sec4.8}
------------------------

Total RNA was isolated from hPSCs and their derivatives using ISOGENE (Nippon Gene). cDNA was synthesized using 500 ng of total RNA with a Superscript VILO cDNA synthesis kit (Invitrogen). Real-time RT-PCR was performed with SYBR green PCR Master Mix (Applied Biosystems) using an Applied Biosystems StemOnePlus real-time PCR systems. Relative quantification was performed against a standard curve, and the values were normalized against the input determined for the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase. The primer sequences used in this study are described in [Table S4](#app2){ref-type="sec"}. In addition, we confirmed that every beta integrin primer used in this manuscript showed a similar amplification efficacy ([Table S5](#app2){ref-type="sec"}). The amplification efficiency was calculated from the slope of the standard curve according to the following formula: e = 10^∧^(−1/slope)-1. Every beta integrin primer used in this manuscript showed a similar amplification efficacy.

Immunohistochemistry {#sec4.9}
--------------------

The cells were fixed with 4% PFA for 15 min and then blocked with PBS containing 2% FBS, 2% bovine serum albumin (BSA), and 0.1% Triton X-100 (Wako Pure Chemicals Industries) for 1 hr. The cells were incubated with primary antibody (described in [Table S2](#app2){ref-type="sec"}) at 4°C for overnight, followed by incubation with a secondary antibody (described in [Table S3](#app2){ref-type="sec"}) at room temperature for 1 hr. Nuclei were counterstained with DAPI (blue).

ELISA {#sec4.10}
-----

The hPSC-derived HBC P0, HBC P10, and HBC clone were differentiated into the hepatocyte-like cells as described in [Figure 4](#fig4){ref-type="fig"}A. The culture supernatants, which were incubated for 24 hr after fresh medium was added, were collected and analyzed for the amount of ALB secretion by ELISA. ELISA kits for ALB were purchased from Bethyl Laboratories. The amount of ALB secretion was calculated according to each standard followed by normalization to the protein content per well. The human ALB amount in mice serum was also examined by ELISA.

Transplantation of the hESC-Derived HBCs {#sec4.11}
----------------------------------------

The hESC-derived HBCs were dissociated using accutase and then suspended with maintenance DMEM/F12 medium without serum. Eight- to 10-week-old Rag2/IL2Rg double-knockout mice were prepared. The hESC-derived HBCs (1 × 10^6^ cells) were transplanted 24 hr after administration of CCl~4~ (4 ml/kg) by intrasplenical injection. Recipient mouse liver and blood were harvested at 2 weeks after transplantation. The livers were fixed with 4% PFA and processed for immunohistochemistry. Human hepatocytes producing the ALB, AFP, and αAT protein were identified in mouse liver by an antibody specifically recognizing human but not mouse albumin. In addition, serum was extracted and subjected to ELISA analysis. All animal experiments were conducted in accordance with institutional guidelines.

Urea Secretion {#sec4.12}
--------------

The hPSC-derived HBC P0, HBC P10, and HBC clone were differentiated into hepatocyte-like cells as described in [Figure 4](#fig4){ref-type="fig"}A. The culture supernatants, which were incubated for 24 hr after fresh medium was added, were collected and analyzed for the amount of urea secretion. The urea measurement kits were purchased from BioAssay Systems. The amount of urea secretion was calculated according to each standard followed by normalization to the protein content per well. In [Figure S5](#app2){ref-type="sec"}B, both the HBC-derived hepatocyte-like cells and primary human hepatocytes (PHs) (three lots of cryopreserved human hepatocytes were used), that were cultured for 48 hr after the cells were plated (PH 48 hr), were cultured in HCM (containing glutamine) or DMEM (not containing glutamine; Wako) in the presence or absence of 1 mM ammonium chloride (NH~4~Cl, Wako) for 24 hr, and then the amount of urea secretion was measured.

Primary Human Hepatocytes {#sec4.13}
-------------------------

Three lots of cryopreserved human hepatocytes (lot Hu8072 \[CellzDirect\], HC2-14, and HC10-101 \[Xenotech\]) were used. The vials of hepatocytes were rapidly thawed in a shaking water bath at 37°C; the contents of the vial were emptied into prewarmed Cryopreserved Hepatocyte Recovery Medium (Gibco) and the suspension was centrifuged at 100 g for 10 min at room temperature. The hepatocytes were seeded at 1.25 × 10^5^ cells/cm^2^ in HCM (Lonza) containing 10% fetal calf serum (FCS) (Gibco) onto type I collagen-coated 12-well plates. The medium was replaced with hepatocyte culture medium containing 10% FCS 6 hr after seeding. The hepatocytes, which were cultured 48 hr after plating the cells, were used in the experiments.

Adhesion-Blocking Assay Using Integrin Antibody {#sec4.14}
-----------------------------------------------

Twelve-well plates were coated with human recombinant LN111, 211, 411, or 511 (all from BioLamina) and blocked by 1% heat-denatured BSA containing PBS. The hESC-derived single cells were incubated with function-blocking antibodies to integrin α6 and β1 (at the concentrations as recommended by the manufacturer) for 30 min, plated on a human LN111-coated 12-well dish, and allowed to adhere for 1 hr at 37°C. After unattached cells were removed, the remaining adherent cells were fixed for 20 min with 5% glutaraldehyde. The hESC-derived cells that had adhered to the wells were stained with 200 μl of 0.3% crystal violet (Wako) solution at room temperature for 15 min. Excess crystal violet was then removed, and the wells were washed three times. Fixed crystal violet was solubilized in 200 μl of 100% ethanol at room temperature for 15 min. Cell viability was estimated by measuring the absorbance at 595 nm of each well using a microtiter plate reader (Sunrise, Tecan).

CYP Activity {#sec4.15}
------------

To measure the CYP1A2, 2C9, and 3A4 activity of the cells, we performed lytic assays by using P450-GloTM CYP1A2, 2C9, and 3A4 Assay Kits (Promega), respectively. We measured the fluorescence activity with a luminometer (Lumat LB 9507; Berthold) according to the manufacturer's instructions. The CYP activity was normalized with the protein content per well.

Karyotyping {#sec4.16}
-----------

This experiment was carried out at Chromosome Science Labo.

Cell Viability Tests {#sec4.17}
--------------------

Cell viability was assessed by using a WST-8 assay kit (Dojindo), and the results are presented in [Figure S5](#app2){ref-type="sec"}C. After treatment with test compounds, such as acetaminophen (Wako) and troglitazone (Wako) for 24 hr, the cell viability was measured. The control cells were incubated in the absence of test compounds and were considered to have 100% viability value. Controls were treated with DMSO (final concentration 0.1%).

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5 and Tables S1--S5
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![The Human ESC-Derived HBCs Selectively Attached to a Human LN111-Coated Dish via Integrin α6 and β1\
(A) The procedure for the differentiation of hESCs (H9) into hepatoblast-like cells (HBCs) is presented schematically. Details are described in the [Experimental Procedures](#sec4){ref-type="sec"}.\
(B) Phase-contrast micrographs of the hESC-derived HBCs (red) and non-HBCs (NHBCs) (green) are shown.\
(C) The hESC-derived cells (day 9) were subjected to immunostaining with anti-AFP (red) antibodies. The percentage of AFP-positive cells was examined on day 0 or 9 by using FACS analysis. Data represent the mean ± SD from ten independent experiments. Cells on "day 0" and "day 9" were compared using Student's t test (p \< 0.01).\
(D) On day 9, the hESC-derived HBCs and NHBCs were manually picked, and the gene expression levels of *AFP* and pan-hepatoblast markers (*CD133*, *EpCAM*, *CK8*, and *CK18*) were measured by real-time RT-PCR. The gene expression levels of *AFP* and pan-hepatoblast markers in the hESC-derived cells (day 9; bulk) were taken as 1.0. Data represent the mean ± SD from four independent experiments. The gene expression levels in the HBCs were significantly different among the three groups (bulk, HBCs, and NHBCs) based on analysis with one-way ANOVA followed by Bonferroni post hoc tests (p \< 0.05).\
(E) The hESC-derived cells (day 9; bulk), HBCs, and NHBCs were plated onto human LN111-, 211-, 411-, or 511-coated dishes, and the attached cells were counted at 60 min after plating. The cell number that was initially plated was taken as 1.0. Data represent the mean ± SD from four independent experiments. The number of attached HBCs on LN111-coated dishes were significantly different among three groups (bulk, HBCs, and NHBCs) based on analysis with one-way ANOVA followed by Bonferroni post hoc tests (p \< 0.05).\
(F) The gene expression levels of the indicated integrins were measured in the hESC-derived cells (day 9; bulk), HBCs, and NHBCs by real-time RT-PCR. Data represent the mean ± SD from four independent experiments. The gene expression levels of *integrin α3* and *α6* in the HBCs were significantly different among three groups (bulk, HBCs, and NHBCs) based on analysis with one-way ANOVA followed by Bonferroni post hoc tests (p \< 0.05).\
(G) The adhesion of the hESC-derived HBCs to human LN111-, 211-, 411-, or 511-coated dishes was examined by using the indicated integrin antibodies. IgG antibodies were used as a control for uninhibited cell adhesion. The number of attached cells was estimated at 60 min after plating. The cell number in the control IgG-treated group was taken as 1.0. Data represent the mean ± SD from three independent experiments. "Control IgG" and "anti-integrin α6 or integrin β1" were compared using Student's t test. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001.\
See also [Figure S1](#app2){ref-type="sec"} and [Tables S2--S5](#app2){ref-type="sec"}.](gr1){#fig1}

![The hESC-Derived HBCs Could Be Proliferated and Maintained on a Human LN111-Coated Dish\
(A) The hESC (H9)-derived cells (day 9) were plated onto a human LN111-coated dish. At 15 min after plating, the unattached cells were removed.\
(B) The hESC (H9)-derived cells (day 9) were plated onto a human LN111, 211, 411, or 511-coated dish, and then the cell number were counted on days 10, 12, 14, and 16. The cell number on day 10 was taken as 1.0. Data represent the mean ± SD from three independent experiments. "LN111" was significantly different among four groups (LN111, 211, 411, and 511) on day 14 and 16 based on analysis with one-way ANOVA followed by Bonferroni post hoc tests (p \< 0.05).\
(C) The hESC-derived cells (day 9) were plated onto a human LN111, 211, 411, or 511-coated dish. The percentage of AFP-positive cells was examined by using FACS analysis on day 9 (before passage and after passage \[HBC P0\]) or day 16. Data represent the mean ± SD from three independent experiments.\
(D) The hESC-derived cells cultured on a human LN111-coated dish for 7 days were subjected to immunostaining with anti-AFP (green) antibodies.\
(E) The hESC-derived cells (day 9) were plated onto human LN111, 211, 411, or 511-coated dishes. The gene expression levels of *AFP* and pan-hepatoblast markers (*CD133*, *EpCAM*, *CK8*, and, *CK18*) were measured by real-time RT-PCR on day 16. The gene expression levels in the hESC-derived HBCs (the LN111-attached cells were collected at 15 min after plating) were taken as 1.0.\
(F) The HBCs derived from hESCs (H9) or hiPSCs (Dotcom) were cultured and cell growth was analyzed by obtaining a cell count at each passage. Data represent the mean ± SD from three independent experiments.\
(G) The percentage of AFP-positive cells was examined by using FACS analysis on day 9 (before passage), P1 (HBCs passaged once), P10 (HBCs passaged ten times), and P15 (HBCs passaged 15 times). Data represent the mean ± SD from seven independent experiments.\
See also [Tables S2](#app2){ref-type="sec"} and [S3](#app2){ref-type="sec"}.](gr2){#fig2}

![The hESC-Derived HBCs Were Characterized\
(A and B) The hESCs (H9) were differentiated according to [Figure 1](#fig1){ref-type="fig"}A and then passaged onto a human LN111-coated dish. The attached cells (hESC-derived HBCs \[HBC P0\]) were collected at 15 min after plating. The percentage of AFP-positive, ALB-positive, CK7-positive, CK19-positive (A), and integrin α6- and integrin β1-double positive (B) cells in the hESC-derived HBC P0, HBC P1 (HBCs passaged once), and HBC P10 (HBCs passaged ten times) populations was estimated by using FACS analysis. Data represent the mean ± SD from seven independent experiments.\
(C--F) The gene expression levels of hepatic stem cell markers (C), pan-hepatoblast markers (D), hepatoblast markers (E), and mature hepatocyte (*CYP3A4*, *7A1*, *2C9*, and *TO*) or cholangiocyte markers (*integrin β4* and *SOX9*) (F) were measured in the definitive endoderm cells, HBC P0, HBC P1, or HBC P10 by real-time RT-PCR.\
(G) The gene expression levels of *CD13*, *CK7*, *DLK1*, and *PROX1* were measured in the hESC-derived definitive endoderm cells, HBC P0, HBC P1, or HBC P10 by real-time RT-PCR. Data represent the mean ± SD from three independent experiments. Statistical significance was evaluated by ANOVA followed by Bonferroni post hoc tests to compare four groups (DE cells, HBC P0, HBC P1, and HBC P10). Groups that do not share the same letter are significantly different from each other (p \< 0.05). DE, definitive endoderm cells.\
See also [Figures S2](#app2){ref-type="sec"} and [S3](#app2){ref-type="sec"} and [Tables S2--S4](#app2){ref-type="sec"}.](gr3){#fig3}

![The hESC-Derived HBCs Could Differentiate into Both Hepatic and Biliary Lineages\
(A) The procedure for differentiation of the hESC (H9)-derived HBC P0, HBC P10, or HBC clone into the hepatocyte-like cells is presented schematically. Details are described in [Experimental Procedures](#sec4){ref-type="sec"}.\
(B) Phase-contrast micrographs of the HBC P10-derived hepatocyte-like cells are shown.\
(C) The HBC P10-derived hepatocyte-like cells were subjected to immunostaining with anti-CYP3A4 (green), anti-αAT (red), and anti-ALB (red) antibodies.\
(D and E) The gene expression levels of hepatocyte (D) or cholangiocyte (E) markers in HBC P0-, HBC P10-, or HBC clone-derived hepatocyte-like cells were measured by real-time RT-PCR after 14 days of hepatocyte differentiation. In (D), the gene expression levels in PH 48 hr were taken as 1.0. In (E), the gene expression levels in HBC P10 (before differentiation) were taken as 1.0. Data represent the mean ± SD from three independent experiments. Student's t test indicated that gene expression levels of the hepatocyte markers in "after" were significantly higher than those in "before" (p \< 0.01).\
(F) The efficiency of hepatocyte differentiation was measured by estimating the percentage of ASGR1-positive cells using FACS analysis.\
(G) The amounts of ALB (left) and urea (right) secretion were examined. Data represent the mean ± SD from three independent experiments. Student's t test indicated that the percentage of ASGR1-positive cells, the ALB secretion level, and urea secretion level in "after" were significantly higher than those in "before" (p \< 0.01).\
(H) The procedure for the differentiation of the hESC-derived HBC P0, HBC P10, or HBC clone into cholangiocyte-like cells is presented schematically. Details are described in [Experimental Procedures](#sec4){ref-type="sec"}.\
(I) Phase-contrast micrographs of the HBC P10-derived cholangiocyte-like cells are shown.\
(J) The HBC P10-derived cholangiocyte-like cells were subjected to immunostaining with anti-CK7 (red) antibodies.\
(K and L) The gene expression levels of hepatocyte (K) or cholangiocyte (L) markers in the HBC P0-, HBC P10-, or HBC clone-derived cholangiocyte-like cells were measured by real-time RT-PCR after 14 days of cholangiocyte differentiation. In (K), the gene expression levels in PH 48 hr were taken as 1.0. In (L), the gene expression levels in HBC P10 (before cholangiocyte differentiation) were taken as 1.0. Data represent the mean ± SD from three independent experiments. Student's t test indicated that the gene expression levels of cholangiocyte markers in "after" were significantly higher than those in "before" (p \< 0.01). "Before" indicates the HBCs before hepatocyte or cholangiocyte differentiation; "After" indicates the HBCs after hepatocyte or cholangiocyte differentiation.\
See also [Figures S4](#app2){ref-type="sec"} and [S5](#app2){ref-type="sec"} and [Tables S1--S4](#app2){ref-type="sec"}.](gr4){#fig4}

![The hESC-Derived HBCs Were Integrated into the Mouse Liver Parenchyma\
(A) The procedure for transplantation of the hESC (H9)-derived HBC P0 and HBC P10 into CCl~4~ (4 ml/kg)-treated Rag2/IL2 receptor gamma double-knockout mice is presented schematically.\
(B) The human ALB level in recipient mouse serum was measured at 2 weeks after transplantation. Data represent the mean ± SD from six to eight mice in each group. Statistical significance was evaluated by ANOVA followed by Bonferroni post hoc tests to compare all groups. Groups that do not share the same letter are significantly different from each other (p \< 0.05).\
(C) Expressions of the ALB (green) in the liver of transplanted mice were examined by immunohistochemistry at 2 weeks after transplantation.\
(D and E) The expressions of AFP (red), ALB (green) (D), and αAT (red) (E) were examined by immunohistochemistry at 2 weeks after hESC-derived HBC P10 transplantation. White arrows show transplanted cells, which have double nuclei.\
See also [Tables S2](#app2){ref-type="sec"} and [S3](#app2){ref-type="sec"}.](gr5){#fig5}
